These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21092172)

  • 1. Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma.
    Cao W; Zhang ZY; Xu Q; Sun Q; Yan M; Zhang J; Zhang P; Han ZG; Chen WT
    Mol Cancer; 2010 Nov; 9():296. PubMed ID: 21092172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas.
    Beder LB; Gunduz M; Hotomi M; Fujihara K; Shimada J; Tamura S; Gunduz E; Fukushima K; Yaykasli K; Grenman R; Shimizu K; Yamanaka N
    Cancer Sci; 2009 May; 100(5):873-80. PubMed ID: 19445022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
    Overmeer RM; Henken FE; Bierkens M; Wilting SM; Timmerman I; Meijer CJ; Snijders PJ; Steenbergen RD
    J Pathol; 2009 Nov; 219(3):327-36. PubMed ID: 19662663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
    Horne HN; Lee PS; Murphy SK; Alonso MA; Olson JA; Marks JR
    Mol Cancer Res; 2009 Feb; 7(2):199-209. PubMed ID: 19208741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
    Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
    Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
    Zolk O; Schnepf R; Muschler M; Fromm MF; Wendler O; Traxdorf M; Iro H; Zenk J
    Am J Pathol; 2013 Jan; 182(1):234-43. PubMed ID: 23137910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma.
    Šutić M; Baranašić J; Bilić LK; Bilić M; Jakovčević A; Brčić L; Seiwerth S; Jakopović M; Samaržija M; Zechner U; Knežević J
    Diagn Pathol; 2021 Feb; 16(1):17. PubMed ID: 33637109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.
    Demokan S; Chuang AY; Pattani KM; Sidransky D; Koch W; Califano JA
    Oncol Rep; 2014 Feb; 31(2):1014-20. PubMed ID: 24337411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of MAL expression in precancerous lesions of the esophagus.
    Mimori K; Nishida K; Nakamura Y; Ieta K; Yoshikawa Y; Sasaki A; Ishii H; Alonso MA; Mori M
    Ann Surg Oncol; 2007 May; 14(5):1670-7. PubMed ID: 17151798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma.
    Pattani KM; Soudry E; Glazer CA; Ochs MF; Wang H; Schussel J; Sun W; Hennessey P; Mydlarz W; Loyo M; Demokan S; Smith IM; Califano JA
    PLoS One; 2012; 7(9):e45534. PubMed ID: 23029077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermethylated MAL gene - a silent marker of early colon tumorigenesis.
    Lind GE; Ahlquist T; Kolberg M; Berg M; Eknaes M; Alonso MA; Kallioniemi A; Meling GI; Skotheim RI; Rognum TO; Thiis-Evensen E; Lothe RA
    J Transl Med; 2008 Mar; 6():13. PubMed ID: 18346269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.
    Chaisaingmongkol J; Popanda O; Warta R; Dyckhoff G; Herpel E; Geiselhart L; Claus R; Lasitschka F; Campos B; Oakes CC; Bermejo JL; Herold-Mende C; Plass C; Schmezer P
    Oncogene; 2012 Dec; 31(49):5108-16. PubMed ID: 22286769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential gene expression between squamous cell carcinoma of esophageus and its normal epithelium; altered pattern of mal, akr1c2, and rab11a expression.
    Kazemi-Noureini S; Colonna-Romano S; Ziaee AA; Malboobi MA; Yazdanbod M; Setayeshgar P; Maresca B
    World J Gastroenterol; 2004 Jun; 10(12):1716-21. PubMed ID: 15188492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 antisense-mediated growth inhibition in a head and neck squamous cell carcinoma cell line.
    Bran G; Götte K; Riedel K; Hörmann K; Riedel F
    In Vivo; 2011; 25(4):579-84. PubMed ID: 21708999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer.
    Buffart TE; Overmeer RM; Steenbergen RD; Tijssen M; van Grieken NC; Snijders PJ; Grabsch HI; van de Velde CJ; Carvalho B; Meijer GA
    Br J Cancer; 2008 Dec; 99(11):1802-7. PubMed ID: 19002170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma.
    Bennett KL; Karpenko M; Lin MT; Claus R; Arab K; Dyckhoff G; Plinkert P; Herpel E; Smiraglia D; Plass C
    Cancer Res; 2008 Jun; 68(12):4494-9. PubMed ID: 18559491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.
    Calmon MF; Rodrigues RV; Kaneto CM; Moura RP; Silva SD; Mota LD; Pinheiro DG; Torres C; de Carvalho AF; Cury PM; Nunes FD; Nishimoto IN; Soares FA; da Silva AM; Kowalski LP; Brentani H; Zanelli CF; Silva WA; Rahal P; Tajara EH; Carraro DM; Camargo AA; Valentini SR
    Neoplasia; 2009 Dec; 11(12):1329-39. PubMed ID: 20019841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway.
    Mimori K; Shiraishi T; Mashino K; Sonoda H; Yamashita K; Yoshinaga K; Masuda T; Utsunomiya T; Alonso MA; Inoue H; Mori M
    Oncogene; 2003 May; 22(22):3463-71. PubMed ID: 12776198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
    Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
    J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
    Schmitt K; Molfenter B; Laureano NK; Tawk B; Bieg M; Hostench XP; Weichenhan D; Ullrich ND; Shang V; Richter D; Stögbauer F; Schroeder L; de Bem Prunes B; Visioli F; Rados PV; Jou A; Plath M; Federspil PA; Thierauf J; Döscher J; Weissinger SE; Hoffmann TK; Wagner S; Wittekindt C; Ishaque N; Eils R; Klussmann JP; Holzinger D; Plass C; Abdollahi A; Freier K; Weichert W; Zaoui K; Hess J
    Int J Cancer; 2019 Dec; 145(12):3299-3310. PubMed ID: 31135957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.